These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21674128)

  • 1. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
    Adamsen BL; Kravik KL; De Angelis PM
    Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment.
    Adamsen BL; Kravik KL; Clausen OP; De Angelis PM
    Int J Oncol; 2007 Dec; 31(6):1491-500. PubMed ID: 17982676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
    Chung H; Chaudhry J; Lopez CG; Carethers JM
    Cancer Biol Ther; 2010 Dec; 10(11):1147-56. PubMed ID: 20930505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
    De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
    Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
    Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
    Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of geno- and cytotoxicity of methylnitrosourea on MMR-proficient and MMR-deficient human tumor cell lines].
    Tronov VA; Kramarenko II; Smirnova TD; Terekhov SM
    Tsitologiia; 2006; 48(1):19-27. PubMed ID: 16568831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
    de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
    BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
    Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
    Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
    de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
    Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?
    El-Awady RA; Saleh EM; Dahm-Daphi J
    Anticancer Drugs; 2010 Mar; 21(3):277-87. PubMed ID: 20075715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment.
    Yang SY; Miah A; Sales KM; Fuller B; Seifalian AM; Winslet M
    Int J Oncol; 2011 Jun; 38(6):1695-702. PubMed ID: 21424124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.
    De Angelis PM; Kravik KL; Tunheim SH; Haug T; Reichelt WH
    Mol Cancer; 2004 Apr; 3():11. PubMed ID: 15109396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation.
    Xavier CP; Lima CF; Rohde M; Pereira-Wilson C
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1449-57. PubMed ID: 21479885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil.
    Dörsam B; Göder A; Seiwert N; Kaina B; Fahrer J
    Arch Toxicol; 2015 Oct; 89(10):1829-46. PubMed ID: 25526924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.
    Petak I; Tillman DM; Houghton JA
    Clin Cancer Res; 2000 Nov; 6(11):4432-41. PubMed ID: 11106264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.